Uterocefum Foaming intrauterine tablets (10 tablets)
DESCRIPTION
Uterocef (Uterocefum) - a drug for the prevention and treatment of inflammatory processes of the uterus after childbirth in cows. The drug is an oblong tablet, biconvex or flat, from white to yellow with a mosaic structure.
COMPOSITION
One tablet contains: 500 mg of sodium ceftiofur and 100 mg of propranolol hydrochloride, excipients (magnesium stearate, talc), as well as a foaming base (sodium bicarbonate, tartaric acid) - up to 15 g.
PHARMACOLOGICAL PROPERTIES
The drug has a bactericidal effect, and also increases the contractile activity of the myometrium.
Ceftiofur, which is part of the drug, is a third-generation cephalosporin antibiotic with a broad spectrum of action that has a bactericidal effect on gram-negative and gram-positive bacteria, including strains that produce lactamase: Escherichia coli, Pasteurella spp., Salm onella spp .. Streptococcus sppccus, Staphil spp. .. Bacillus spp., Proteus spp .; as well as some of the tammas of anaerobes: Klebsiela, Citrobacter. Enterobacter, Fusobacterium necrophorum.
Propranolol hydrochloride is an indiscriminate B-blocker that has a stimulating effect on the smooth muscles of the uterus, increases the contractile activity of the myometrium.
Ceftiofur acts bactericidal, inhibits the enzyme transpeptidase, disrupts the synthesis of peptidoglucanamukopeptide of the cell membrane, which leads to disruption of the growth of the cell wall of the microorganism and lysis of bacteria, and propranolol hydrochloride has a membrane stabilizing effect and weakens the effect of sympathetic impulses on adrenergic receptors.
In the uterine cavity, ceftiofur is rapidly metabolized to form desfuroylceftiofur, which has an activity equivalent to ceftiofur against bacteria. This active metabolite reversibly binds to proteins and accumulates in the focus of infection, while its activity does not decrease in the presence of necrotic tissues.
With intrauterine use, less than 1% of the drug is absorbed and the systemic effect is practically not manifested.
PURPOSE
The tablets are intended for the prevention and treatment of inflammatory processes of the uterus after obstetric aid with complicated and pathological childbirth, surgical separation of the placenta, abortion, and acute endometritis in cows.
DOSAGE AND APPLICATION
Before the introduction of the tablets, the external genital organs are sanitized.
For prophylactic purposes, 1 tablet is administered once immediately after the separation of the placenta, abortion or obstetric aid. Due to the foaming base of the drug, after the introduction of one tablet, at least 700 ml of foam is formed, which ensures maximum contact of the active substance with the endometrium.
For therapeutic purposes, 1 tablet is injected into the uterus with an interval of 24-48 hours until clinical recovery.
In the absence of liquid contents in the uterine cavity, 100 - 150 ml of sterile liquid (boiled water) should be injected before the introduction of the tablet.
SPECIAL INSTRUCTIONS
The use of tablets does not exclude the use of other systemic drugs.
Slaughter for meat of cattle is carried out no earlier than 3 days after the last use of the drug. The meat of animals that were forcedly killed before the expiration of the specified period can be used for feeding fur-bearing animals.
SIDE EFFECTS
Side effects and complications during the period of using the tablets in accordance with the instructions for use have not been established.
SHELF LIFE AND STORAGE
The tablets are stored in a dark place at a temperature not exceeding plus 30 В° C. Shelf life 18 months from the date of manufacture, subject to storage conditions.
PACKAGING
Tablets are packed in a polymer container of 10 pieces.
Specifications
Bonus points
0
KolVUP
1
Manufacturer
Belekotekhnika
Temperature regime
from 0 to +30
Teaser
for the prevention and treatment of inflammatory processes of the uterus after childbirth in cows
'